Stocks Health care ONCO
NASDAQ · Health careOnconetix, Inc. (ONCO)
Onconetix, Inc. brought in $645.8K of revenue over the twelve months to June 30, 2026, down 51.3% from a year earlier. It posted a net loss of $10.2M. At June 30, 2026 it held $5.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Onconetix, Inc.
- Net worth
- Onconetix, Inc. has a market value (market cap) of $14.8M at the latest share price, and shareholders' equity of $13.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $815.4K (-67.7% year on year), with a net loss of $14M. Over the 12 months to June 30, 2026: revenue $645.8K, net loss $10.2M.
- Cash flow
- In fiscal 2025 operations used $9.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Onconetix, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Onconetix, Inc. declared dividends of $1.23 per share in fiscal 2022.
What Onconetix, Inc. does
Onconetix, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ONCO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $815.4K | -$14M | -$16.56 | n/a |
| 2024 | $2.5M | -$58.7M | -$1,823.39 | -$10.5M |
| 2023 | $58.5K | -$37.4M | -$7,433.82 | -$13.6M |
| 2022 | n/a | -$13.4M | -$3,733.88 | -$8.7M |
| 2022 | n/a | -$3.4M | -$4,276.99 | -$2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ONCO ranks in Health care
Dividends
Onconetix, Inc. declared $1.23 per share in fiscal 2022.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2022 | $1.23 | n/a | n/a |
Latest SEC filings
What Onconetix, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026Preliminary proxy statement PRE 14A
- September 14, 2026Additional proxy material DEFA14A
- September 14, 2026
- September 14, 2026Form 425 filing 425
- September 3, 2026Form 425 filing 425
- August 31, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 84% to $17.1K versus the same quarter last year; diluted EPS -$1.28 versus -$237.91.
- August 12, 2026IPO registration S-1
- August 6, 2026Form 425 filing 425
- July 29, 2026
Insider trades
What the people running Onconetix, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 21, 2026 | Hrt Financial LP10% owner | Sold | 49,710 | $34.3K |
| April 20, 2026 | Hrt Financial LP10% owner | Sold | 94,462 | $70.8K |
| April 17, 2026 | Hrt Financial LP10% owner | Bought | 34,636 | $25.3K |
| April 16, 2026 | Hrt Financial LP10% owner | Sold | 53,867 | $39.3K |
| April 15, 2026 | Hrt Financial LP10% owner | Bought | 92,554 | $70.3K |
| April 14, 2026 | Hrt Financial LP10% owner | Bought | 74,350 | $57.2K |
Who owns ONCO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Altos Venture AG13D, may seek influence | 35.8% | July 16, 2025 |
| Keystone Capital Partners, LLC13G, passive with 2 related filers | 6.1% | July 27, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 33,649 shares in total, about $126.5K at the last price.
| Holder | Shares |
|---|---|
| Hrt Financial LP10% owner | 33,649 |
Questions about ONCO
What does Onconetix, Inc. do?
Onconetix, Inc. is a company in the Health care sector, listed on NASDAQ as ONCO. Its shares trade on NASDAQ under the ticker ONCO.
What is Onconetix, Inc.'s net worth?
Onconetix, Inc. has a market value (market cap) of $14.8M at the latest share price, and shareholders' equity of $13.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Onconetix, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $10.2M on revenue of $645.8K.
How much revenue does Onconetix, Inc. make?
Over the twelve months to June 30, 2026 Onconetix, Inc. reported revenue of $645.8K. That is 51.3% less than a year earlier.
When did Onconetix, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the preliminary proxy statement from September 17, 2026.
When is Onconetix, Inc.'s next earnings report?
Onconetix, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Onconetix, Inc. pay a dividend?
Yes. Onconetix, Inc. declared dividends of $1.23 per share in fiscal 2022.
Similar companies
Compare ONCO with
Follow ONCO
Get an email when Onconetix, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Onconetix, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.